ID   SW480/nkR
AC   CVCL_AT66
DR   cancercelllines; CVCL_AT66
DR   Wikidata; Q54971169
RX   Patent=US7989001;
CC   Population: Caucasian.
CC   Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1338Ter (c.4012C>T); ClinVar=VCV000000801; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro309Ser (c.925C>T); ClinVar=VCV000458575; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: In situ; Colon; UBERON=UBERON_0001155.
DI   NCIt; C4349; Colon adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0546 ! SW480
SX   Male
AG   51Y
CA   Cancer cell line
DT   Created: 02-05-16; Last updated: 05-10-23; Version: 14
//
RX   Patent=US7989001;
RA   Kim U., Cohen S.A.;
RT   "Method of separating tumor cells with and without lymphotropic
RT   metastatic potential in a human carcinoma.";
RL   Patent number US7989001, 02-Aug-2011.
//